Pharmaceutical giant Pfizer is to launch a new research unit aimed at exploring the use of stem cells to develop drugs that could repair failing organs and treat degenerative diseases.
The unit, known as Pfizer Regenerative Medicine, will be co-located in Cambridge in the UK and Cambridge, Massachusetts, in the US, and will employ around 70 researchers.
It will build on recent scientific progress in understanding the biology of stem cells to discover and develop a new generation of regenerative medicines for major medical needs.
Rod MacKenzie, head of worldwide research at Pfizer, said: “Pfizer Regenerative Medicine represents a great opportunity to focus world-class research in a field that holds considerable promise for biomedical science and for the treatment of many debilitating conditions such as diabetes and neurodegenerative disorders.”
The president of the company’s Biotherapeutics and Bioinnovation Centre, Corey Goodman, added: “The formation of this new unit represents another key step forward in Pfizer’s commitment to be at the forefront of new approaches in biotherapeutics and bioinnovation and to expand our research efforts and expertise into emerging areas of biomedical science, like regenerative medicine, that have great potential for human health.”
Copyright Press Association 2008